Pfizer Inc. completed its acquisition of Anacor Pharmaceuticals, Inc. According to the company, the transaction terms provided each outstanding share of Anacor to be converted into the right to get $99.25 net in cash, i.e. without any interest but subject to required withholding of taxes.
Pfize Innovative Health Group President, Albert Bourla, said, “Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease, an area of high unmet medical need. We believe that Pfizer is in a position to quickly capitalize on the benefits offered by the combination with Anacor, including the potential for a near-term U.S. product launch and subsequent commercialization of crisaborole, a differentiated asset with compelling clinical data. If approved, crisaborole has the potential to be an important first-line treatment option for patients with mild-to-moderate atopic dermatitis and the physicians who treat them.”
Why this deal >> Read more